Literature DB >> 8758936

Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.

L D Attardi1, S W Lowe, J Brugarolas, T Jacks.   

Abstract

The p53 tumor suppressor limits cellular proliferation by inducing either G1 arrest or apoptosis, depending on the cellular context. To determine if these pathways are mechanistically distinct, we have examined the effects of different p53 mutants in p53 null primary mouse embryo fibroblasts. We chose this system as it is highly physiological and ensures that the interpretation of the results will not be confounded by the presence of endogenous p53 or oncoproteins which target p53. Using single cell microinjection assays for both G1 arrest and apoptosis, with loss-of-function and chimeric gain-of-function mutants, we have demonstrated that transcriptional activation is critical for both processes. Replacement of the p53 activation domain with that of VP16, or replacement of the p53 oligomerization domain with that of GCN4, reconstituted both G1 arrest and apoptosis activities. However, despite the importance of transcriptional activation in both processes, the target gene requirements are different. The p21 cyclin-dependent kinase inhibitor, which has been shown to be a direct target of p53 and a component of the radiation-induced G1 arrest response, is dispensable for oncogene-induced apoptosis, suggesting that these two p53-dependent transcriptional pathways are distinct.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758936      PMCID: PMC452024     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  42 in total

1.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

Authors:  L R Livingstone; A White; J Sprouse; E Livanos; T Jacks; T D Tlsty
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

2.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B.

Authors:  M Debbas; E White
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

Review 3.  The tumor suppressor genes.

Authors:  A J Levine
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

5.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

Authors:  M B Kastan; Q Zhan; W S el-Deiry; F Carrier; T Jacks; W V Walsh; B S Plunkett; B Vogelstein; A J Fornace
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

8.  Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis.

Authors:  S W Lowe; H E Ruley
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

Review 9.  p53 and the Li-Fraumeni syndrome.

Authors:  D Malkin
Journal:  Cancer Genet Cytogenet       Date:  1993-04

10.  p53 oligomerization and DNA looping are linked with transcriptional activation.

Authors:  J E Stenger; P Tegtmeyer; G A Mayr; M Reed; Y Wang; P Wang; P V Hough; I A Mastrangelo
Journal:  EMBO J       Date:  1994-12-15       Impact factor: 11.598

View more
  53 in total

1.  Suppression of E1A-mediated transformation by the p50E4F transcription factor.

Authors:  E R Fernandes; R J Rooney
Journal:  Mol Cell Biol       Date:  1999-07       Impact factor: 4.272

Review 2.  Apoptosis and cancer drug targeting.

Authors:  W R Sellers; D E Fisher
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

3.  Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells.

Authors:  D Chattopadhyay; M K Ghosh; A Mal; M L Harter
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

5.  Mechanism of neem limonoids-induced cell death in cancer: Role of oxidative phosphorylation.

Authors:  Neelu Yadav; Sandeep Kumar; Rahul Kumar; Pragya Srivastava; Leimin Sun; Peter Rapali; Timothy Marlowe; Andrea Schneider; Joseph R Inigo; Jordan O'Malley; Ramesh Londonkar; Raghu Gogada; Ajay K Chaudhary; Nagendra Yadava; Dhyan Chandra
Journal:  Free Radic Biol Med       Date:  2015-11-25       Impact factor: 7.376

6.  Regulation of ES cell differentiation by functional and conformational modulation of p53.

Authors:  K Sabapathy; M Klemm; R Jaenisch; E F Wagner
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

7.  Redundancy of DNA helicases in p53-mediated apoptosis.

Authors:  E A Spillare; X W Wang; C von Kobbe; V A Bohr; I D Hickson; C C Harris
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

8.  The p53-Bcl-2 connection.

Authors:  M T Hemann; S W Lowe
Journal:  Cell Death Differ       Date:  2006-05-19       Impact factor: 15.828

9.  p53 targets identified by protein expression profiling.

Authors:  Rubaiyat Rahman-Roblick; Uwe Johannes Roblick; Ulf Hellman; Paolo Conrotto; Tao Liu; Susanne Becker; Daniel Hirschberg; Hans Jörnvall; Gert Auer; Klas G Wiman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-19       Impact factor: 11.205

10.  NS1- and minute virus of mice-induced cell cycle arrest: involvement of p53 and p21(cip1).

Authors:  A Op De Beeck; J Sobczak-Thepot; H Sirma; F Bourgain; C Brechot; P Caillet-Fauquet
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.